Innoviva (INVA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $20.78, -0.38% vs the prior close of $20.86.
- Volume 550.48K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
INVA dips 0.4% to $20.78. Closed at $20.78, -0.38% vs the prior close of $20.86. Day range $20.56–$20.97, opened at $20.97.
INVA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — INVA dips 0.4% to $20.78
- Closed at $20.78, -0.38% vs the prior close of $20.86. Day range $20.56–$20.97, opened at $20.97.
- Volume was 550.48K shares, 0.7x its 50-day average of 823.61K.
- Price is -0.9% vs its 50-day average ($20.96) and -4.8% vs its 200-day average ($21.82).
- 52-week range $17.10–$25.15; today's close sits at 46% of that range, 17.4% below the 52-week high.
Oct 15, 2026 — INVA dips 0.5% to $20.86
- Closed at $20.86, -0.52% vs the prior close of $20.97. Day range $20.83–$21.76, opened at $21.33.
- Volume was 673.00K shares, 0.8x its 50-day average of 824.21K.
- Price is -0.5% vs its 50-day average ($20.97) and -4.4% vs its 200-day average ($21.81).
- 52-week range $16.52–$25.15; today's close sits at 50% of that range, 17.1% below the 52-week high.
Oct 14, 2026 — INVA rises 1.1% to $20.97
- Closed at $20.97, +1.11% vs the prior close of $20.74. Day range $20.73–$21.18, opened at $20.79.
- Volume was 673.50K shares, 0.8x its 50-day average of 822.03K.
- Price is +0.0% vs its 50-day average ($20.96) and -3.8% vs its 200-day average ($21.81).
- 52-week range $16.52–$25.15; today's close sits at 52% of that range, 16.6% below the 52-week high.
Oct 13, 2026 — INVA slides 3.3% to $20.74
- Closed at $20.74, -3.31% vs the prior close of $21.45. Day range $20.71–$21.55, opened at $21.55.
- Volume was 811.60K shares, 1.0x its 50-day average of 821.78K.
- Price is -1.1% vs its 50-day average ($20.96) and -4.9% vs its 200-day average ($21.80).
- 52-week range $16.52–$25.15; today's close sits at 49% of that range, 17.5% below the 52-week high.
Oct 12, 2026 — INVA rises 1.1% to $21.45, a 1-month high
- Closed at $21.45, +1.13% vs the prior close of $21.21. Day range $21.12–$21.48, opened at $21.27.
- Volume was 521.20K shares, 0.6x its 50-day average of 821.52K.
- Price is +2.3% vs its 50-day average ($20.96) and -1.6% vs its 200-day average ($21.80).
- 52-week range $16.52–$25.15; today's close sits at 57% of that range, 14.7% below the 52-week high.
Oct 9, 2026 — INVA rises 1.6% to $21.21
- Closed at $21.21, +1.63% vs the prior close of $20.87. Day range $20.78–$21.28, opened at $20.80.
- Volume was 507.50K shares, 0.6x its 50-day average of 821.54K.
- Price is +1.2% vs its 50-day average ($20.95) and -2.6% vs its 200-day average ($21.79).
- 52-week range $16.52–$25.15; today's close sits at 54% of that range, 15.7% below the 52-week high.
Oct 8, 2026 — INVA dips 0.9% to $20.87
- Closed at $20.87, -0.90% vs the prior close of $21.06. Day range $20.73–$21.05, opened at $21.05.
- Volume was 612.30K shares, 0.7x its 50-day average of 820.02K.
- Price is -0.4% vs its 50-day average ($20.95) and -4.2% vs its 200-day average ($21.78).
- 52-week range $16.52–$25.15; today's close sits at 50% of that range, 17.0% below the 52-week high.
Oct 7, 2026 — INVA rises 1.1% to $21.06, 3 up days in a row
- Closed at $21.06, +1.10% vs the prior close of $20.83. Day range $20.78–$21.10, opened at $20.78.
- Volume was 636.30K shares, 0.8x its 50-day average of 819.41K.
- Price is +0.4% vs its 50-day average ($20.97) and -3.3% vs its 200-day average ($21.78).
- 52-week range $16.52–$25.15; today's close sits at 53% of that range, 16.3% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — INVA rises 0.9% to $20.83
- Closed at $20.83, +0.92% vs the prior close of $20.64. Day range $20.62–$20.97, opened at $20.78.
- Volume was 679.60K shares, 0.8x its 50-day average of 818.30K.
- Price is -0.7% vs its 50-day average ($20.98) and -4.3% vs its 200-day average ($21.77).
- 52-week range $16.52–$25.15; today's close sits at 50% of that range, 17.2% below the 52-week high.
Oct 5, 2026 — INVA rises 0.7% to $20.64
- Closed at $20.64, +0.68% vs the prior close of $20.50. Day range $20.45–$20.74, opened at $20.53.
- Volume was 993.40K shares, 1.2x its 50-day average of 809.44K.
- Price is -1.7% vs its 50-day average ($20.99) and -5.2% vs its 200-day average ($21.77).
- 52-week range $16.52–$25.15; today's close sits at 48% of that range, 17.9% below the 52-week high.
Oct 2, 2026 — INVA ends flat (-0.2%) to $20.50
- Closed at $20.50, -0.24% vs the prior close of $20.55. Day range $20.50–$20.76, opened at $20.60.
- Volume was 774.70K shares, 1.0x its 50-day average of 812.79K.
- Price is -2.4% vs its 50-day average ($21.01) and -5.8% vs its 200-day average ($21.76).
- 52-week range $16.52–$25.15; today's close sits at 46% of that range, 18.5% below the 52-week high.
INVA latest news & SEC filings
Every SEC filing by or about INVA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $119.59M (prior year $100.28M) (+19.3% vs Jun 30, 2025)
- Diluted EPS: -$1.14 (prior year $0.77) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade INVA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 25, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.26% (largest 3.5%).
- Liquidity: about 925.69K shares (≈$19.24M) trade per day on average.
- 52-week position: $20.78 vs a range of $17.10–$25.15 (46% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K May 18, 2026.
- Share count: 72.25M shares outstanding (Jul 31, 2026), +14.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
INVA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 20.97 | 20.97 | 20.56 | 20.78 | 550.48K |
| Oct 15, 2026 | 21.33 | 21.76 | 20.83 | 20.86 | 673.00K |
| Oct 14, 2026 | 20.79 | 21.18 | 20.73 | 20.97 | 673.50K |
| Oct 13, 2026 | 21.55 | 21.55 | 20.71 | 20.74 | 811.60K |
| Oct 12, 2026 | 21.27 | 21.48 | 21.12 | 21.45 | 521.20K |
| Oct 9, 2026 | 20.80 | 21.28 | 20.78 | 21.21 | 507.50K |
| Oct 8, 2026 | 21.05 | 21.05 | 20.73 | 20.87 | 612.30K |
| Oct 7, 2026 | 20.78 | 21.10 | 20.78 | 21.06 | 636.30K |
| Oct 6, 2026 | 20.78 | 20.97 | 20.62 | 20.83 | 679.60K |
| Oct 5, 2026 | 20.53 | 20.74 | 20.45 | 20.64 | 993.40K |
| Oct 2, 2026 | 20.60 | 20.76 | 20.50 | 20.50 | 774.70K |
| Oct 1, 2026 | 21.28 | 21.28 | 20.53 | 20.55 | 927.10K |
| Sep 30, 2026 | 21.11 | 21.45 | 21.06 | 21.21 | 1.10M |
| Sep 29, 2026 | 21.19 | 21.19 | 20.74 | 21.11 | 555.80K |
| Sep 28, 2026 | 20.74 | 21.39 | 20.59 | 21.23 | 854.60K |
| Sep 25, 2026 | 20.70 | 20.78 | 20.35 | 20.74 | 623.40K |
| Sep 24, 2026 | 20.28 | 20.79 | 20.28 | 20.66 | 1.37M |
| Sep 23, 2026 | 21.11 | 21.36 | 20.23 | 20.24 | 4.03M |
| Sep 22, 2026 | 21.17 | 21.39 | 20.96 | 20.98 | 931.60K |
| Sep 21, 2026 | 21.10 | 21.27 | 21.00 | 21.04 | 688.50K |
About Innoviva
Innoviva (INVA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BURLINGAME, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1080014.
INVA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mark Dipaolo | Director | May 6, 2026 |
| Jules Haimovitz | Director | May 6, 2026 |
| Josephine Linden | Director | May 20, 2026 |
| Pavel Raifeld | Chief Executive Officer | Aug 24, 2026 |
| Sarah J. Schlesinger | Director | May 6, 2026 |
| Derek A Small | Director | May 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Stephen Basso | Chief Financial Officer | Aug 24, 2026 |
| Pavel Raifeld | Chief Executive Officer | Aug 24, 2026 |
| Marianne Zhen | Chief Accounting Officer | Aug 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
INVA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $411.33M | — | 3.30 | $196.93M |
| Dec 31, 2024 | $358.71M | — | 0.36 | $188.69M |
| Dec 31, 2023 | $310.46M | — | 2.20 | $141.06M |
| Dec 31, 2022 | $331.34M | — | 2.37 | $201.73M |
| Dec 31, 2021 | $391.87M | — | 2.87 | $363.81M |
Latest balance sheet: total assets $1.70B, total liabilities $—, cash $570.39M (as of Jun 30, 2026).
INVA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $20.51 |
| May 6, 2026 | 8-K Item 2.02 (results) | $22.52 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $24.24 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $18.23 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $18.25 |
| May 7, 2025 | 8-K Item 2.02 (results) | $18.74 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $17.90 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $19.92 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on INVA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.